Biotech
Seres Therapeutics
Seres Therapeutics raises $113M Series E at $450M valuation
$113M
Total Raised
Series E
Latest Round
2010
Founded
250+
Employees
200 Sidney Street, Cambridge, MA 02139
1 min read
Quick Facts
Valuation
$450M
Latest Round Size
$113M
Latest Round Date
January 2024
Seres Therapeutics: Series E Funding Round
Seres Therapeutics has successfully raised $113M in Series E funding, reaching a valuation of $450M.
Company Overview
Microbiome therapeutic platform
Funding Details
The Series E round was led by Flagship Pioneering, with participation from Polaris Partners, Fidelity, Nestle Health Science, Takeda Ventures.
Company Information
- Headquarters: 200 Sidney Street, Cambridge, MA 02139
- Founded: 2010
- Employees: 250+
- Category: Biotech
Investment
Seres Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in Series E
- Polaris Partners: Verified investor in Series E
- Fidelity: Verified investor in Series E
- Nestle Health Science: Verified investor in Series E
- Takeda Ventures: Verified investor in Series E
Key Investors
Flagship Pioneering
Lead Investor
Verified investor in Series E
Polaris Partners
Investor
Verified investor in Series E
Fidelity
Investor
Verified investor in Series E
Nestle Health Science
Investor
Verified investor in Series E
Takeda Ventures
Investor
Verified investor in Series E
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M